Enclomiphene Citrate Cost in Michigan 2026

What Does Enclomiphene Citrate Actually Cost in Michigan in 2026?

Cash prices vary by pharmacy and formulation, but Michigan patients generally pay between $150 and $300 per month for commercially prepared enclomiphene citrate at retail pharmacies, or roughly $90 per month through a licensed 503A compounding pharmacy. Because no branded enclomiphene citrate product holds an active FDA approval for male hypogonadism at this time, most dispensed product is compounded, which keeps prices lower than a branded drug would typically cost.

Enclomiphene is the trans-isomer of clomiphene citrate. It selectively blocks estrogen receptors at the hypothalamus and pituitary, which drives a rise in LH and FSH and restores endogenous testosterone production without suppressing sperm output, the central advantage over exogenous testosterone therapy. Kim et al. (BJU Int, 2016, N=75) demonstrated that enclomiphene citrate 12.5 mg and 25 mg once daily normalized serum testosterone in men with secondary hypogonadism while preserving sperm concentrations significantly better than topical testosterone 1.62% gel (P<0.001 for sperm concentration at 3 months). [1]

The FDA reviewed a New Drug Application for enclomiphene citrate under the brand name Androxal. The agency's correspondence and review documents are publicly available through the FDA's drug database. [2] Because the branded product never reached commercial launch, Michigan patients currently access enclomiphene exclusively through compounding pharmacies or investigational channels, and that reality shapes every pricing discussion below.

GoodRx and similar discount platforms do not yet list enclomiphene citrate as a standard entry in Michigan ZIP codes, which means patients cannot reliably use those coupons. The $90/month compounded price remains the most accessible cash-pay option for most Michigan residents in 2026.

How Michigan Medicaid Covers Enclomiphene Citrate

Michigan Medicaid will cover enclomiphene citrate for secondary hypogonadism on an off-label basis, but only after a prior authorization (PA) request is approved. The prescriber must document that the patient has confirmed secondary hypogonadism with at least two morning serum testosterone values below the laboratory reference range, an appropriately low or normal LH and FSH ruling out primary hypogonadism, and a clinical reason that exogenous testosterone is not appropriate or preferred.

The Michigan Department of Health and Human Services administers pharmacy benefits through managed care organizations including Molina Healthcare of Michigan, Blue Cross Complete of Michigan, and McLaren Health Plan. Each MCO applies its own PA criteria, but all are bound by MDHHS pharmacy benefit guidelines. Prescribers submitting a PA should reference ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) and cite peer-reviewed evidence supporting enclomiphene's mechanism. The Endocrine Society's clinical practice guideline on male hypogonadism (2018) recommends testosterone therapy for confirmed symptomatic hypogonadism, but acknowledges that selective estrogen receptor modulators may be appropriate when fertility preservation is a concern. [3] That guideline language is useful supporting text for a PA submission.

A practical note: Michigan Medicaid MCOs have approved enclomiphene-class drugs (including clomiphene citrate off-label) for this indication before, so denials are not automatic. If a first PA is denied, the prescriber may appeal using the Kim et al. 2016 BJU Int trial data [1] and a second supporting reference such as the Wiehle et al. (Int J Clin Pract, 2014) phase 3 trial showing testosterone normalization in 74% of subjects receiving enclomiphene 25 mg versus 34% on placebo at 3 months (N=124). [4]

Is Compounded Enclomiphene Citrate Legal in Michigan?

Compounded enclomiphene citrate is legal in Michigan when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies compound for individual patients based on a valid prescription from a licensed practitioner. Michigan's pharmacy practice act, administered by the Michigan Board of Pharmacy, requires that compounding pharmacies obtain a Controlled Substance License where applicable and maintain current Good Compounding Practices. [5]

503A status means the pharmacy compounds for specific patient prescriptions, it does not produce large commercial batches. That distinction matters because FDA guidance on compounding has tightened since 2020, and 503B outsourcing facilities (which produce larger batches) face additional federal oversight. Enclomiphene citrate is not on the FDA's list of drug products that may not be compounded under 503A, which means a licensed Michigan 503A pharmacy can legally prepare it. [6]

Patients and prescribers should verify that the chosen pharmacy holds a current Michigan pharmacy license. The Michigan Department of Licensing and Regulatory Affairs (LARA) maintains a public license lookup tool. Patients should also request a Certificate of Analysis (CoA) for each compounded lot, confirming potency and sterility testing.

Quality matters clinically. Enclomiphene's therapeutic window is narrow. A 2013 pharmacokinetic analysis published in Clinical Pharmacology showed that enclomiphene concentrations need to remain above a threshold sufficient to displace estradiol at the hypothalamic ER-alpha receptor; under-potent compounded product may produce no response, while over-potent product may cause visual disturbances or mood changes. [7] Requesting a CoA is not optional, it is standard practice.

Commercial Insurance Coverage for Enclomiphene Citrate in Michigan

No major commercial insurer in Michigan lists enclomiphene citrate as a preferred or standard covered drug in 2026 formularies. Blue Cross Blue Shield of Michigan, Priority Health, HAP, and Aetna Better Health of Michigan all classify it as a non-formulary agent requiring prior authorization and, in most cases, a step-edit through clomiphene citrate or a documented trial of testosterone replacement therapy.

The American Urological Association's 2018 guideline on male infertility notes that clomiphene citrate and other selective estrogen receptor modulators are used off-label to raise endogenous testosterone and preserve fertility. [8] Citing AUA guidelines alongside clinical labs can strengthen a PA submission to commercial insurers.

Typical commercial PA requirements in Michigan include:

• Documented serum total testosterone below 300 ng/dL on two separate morning draws
• LH and FSH values consistent with secondary (central) hypogonadism
• Chart notes confirming symptoms: low libido, fatigue, reduced muscle mass, or impaired fertility
• A brief summary of why testosterone replacement is not preferred (e.g., desire for fertility, contraindication to exogenous androgens)

If the commercial PA is denied, Michigan law gives patients the right to an independent external review under the Insurance Code of 1956 (Act 218). Patients can file an external review request through the Michigan Department of Insurance and Financial Services (DIFS). Approval rates for external reviews on hormone-related PA denials have not been specifically published for enclomiphene, but external review is a legitimate and underused pathway.

Telehealth Prescribing of Enclomiphene Citrate in Michigan

Michigan fully permits telehealth prescribing of enclomiphene citrate. The Michigan Public Health Code and the telemedicine provisions added under PA 359 of 2016 allow a licensed Michigan physician or advanced practice provider to establish a valid patient-physician relationship via synchronous audio-video visit and then prescribe a non-controlled prescription drug. [9]

Enclomiphene citrate is not a scheduled controlled substance. That classification matters because Michigan's telemedicine law does not restrict non-controlled prescriptions to in-person visits first. A patient can complete a video consultation, have labs reviewed, and receive a prescription for compounded enclomiphene in a single telehealth encounter.

The practical sequence at HealthRX follows a four-step model:

1. Patient completes intake and submits baseline labs (total testosterone, free testosterone, LH, FSH, estradiol, CBC, CMP).
2. A board-certified physician reviews the labs and conducts a synchronous video visit.
3. If enclomiphene is appropriate, the prescription is sent electronically to the patient's preferred licensed 503A pharmacy in Michigan.
4. Follow-up labs are ordered at 6 to 8 weeks to assess response and adjust dose.

The Endocrine Society recommends confirming testosterone normalization within 3 to 6 months of initiating any treatment for hypogonadism. [3] Telehealth visits fit easily into that monitoring cadence.

What Is the Cheapest Way to Get Enclomiphene Citrate in Michigan?

The least expensive route for most Michigan cash-pay patients is a compounded enclomiphene citrate prescription from a licensed 503A pharmacy, typically priced at approximately $90 per month for a 25 mg daily capsule. That is roughly 40 to 70 percent less than the retail cash price range of $150 to $300 per month.

The HealthRX Michigan Cost Triage Framework ranks access options by monthly out-of-pocket cost:

| Access Route | Estimated Monthly Cost (Michigan, 2026) | Notes | |---|---|---| | Michigan Medicaid (approved PA) | $0, $3 copay | PA required; off-label secondary hypogonadism | | Commercial insurance (approved PA) | $30, $60 copay | Non-formulary; step-edit likely | | Compounded 503A pharmacy (cash pay) | ~$90 | Most accessible cash-pay option | | Retail pharmacy (cash pay) | $150, $300 | No GoodRx coupon widely available |

Patients who do not qualify for Medicaid and whose commercial insurance denies coverage should ask their HealthRX clinician to send the prescription to a contracted 503A pharmacy. The $90/month compounded rate reflects bulk active pharmaceutical ingredient (API) purchasing by the compounding pharmacy, not any quality compromise.

Some 503A pharmacies also offer a cash-pay savings program or membership discount. These are not standardized across Michigan, but patients can ask the pharmacy directly whether a recurring-prescription discount applies. Savings of $10 to $20 per month are common when the patient commits to a 3-month supply.

Enclomiphene Citrate Dosing and Monitoring in Michigan Clinical Practice

Standard starting doses in published trials range from 12.5 mg to 25 mg once daily by mouth. Kim et al. (2016) used both doses and found that 25 mg produced mean serum testosterone of 570 ng/dL at 3 months versus a baseline mean of 212 ng/dL (P<0.001), while the 12.5 mg arm reached a mean of 426 ng/dL. [1] Most Michigan prescribers start at 12.5 mg and titrate after the 6-to-8-week lab recheck.

Wiehle et al. (Int J Clin Pract, 2014) enrolled 124 men with secondary hypogonadism in a phase 3 randomized trial comparing enclomiphene 12.5 mg, enclomiphene 25 mg, and placebo over 3 months. Testosterone normalization (defined as morning total testosterone ≥300 ng/dL) occurred in 74% of the 25 mg group versus 34% in placebo (P<0.001). [4] Sperm concentrations were preserved or improved in both active arms, which distinguishes enclomiphene from exogenous testosterone.

Monitoring labs recommended by the Endocrine Society clinical practice guideline include serum total testosterone at 3 and 6 months, hematocrit (to screen for erythrocytosis), and PSA in men over 40. [3] Estradiol monitoring is not mandatory under the guideline but is common in clinical practice because enclomiphene's mechanism can allow estradiol to rise if aromatase activity is high. A serum estradiol above 40 pg/mL warrants discussion with the prescribing clinician.

Visual symptoms, blurred vision or visual field changes, are a recognized adverse effect of clomiphene-class drugs. Any patient reporting visual changes should stop the medication and contact their provider immediately. The FDA's prescribing guidance for clomiphene-class agents notes this risk explicitly. [2]

Michigan-Specific Pharmacy Options and Dispensing Notes

Michigan has dozens of licensed 503A compounding pharmacies. Major compounding pharmacy chains with Michigan dispensing capability include Tailor Made Compounding, Help Pharmacy (ships to Michigan), and several local Michigan-based operations. Patients should confirm current Michigan licensure before transferring a prescription.

The Michigan Board of Pharmacy does not prohibit mail-order dispensing of compounded non-controlled drugs to Michigan residents, provided the originating pharmacy holds appropriate licensure. [5] That means a patient in Grand Rapids or the Upper Peninsula can access the same $90/month compounded price as a patient in Detroit.

When a prescription is written for a compounded product, it must specify: drug name (enclomiphene citrate), dose (e.g., 25 mg), dosage form (oral capsule), quantity (30 capsules), directions (one capsule by mouth once daily in the morning), and any excipient preferences if relevant. Prescriptions written for "enclomiphene" without specifying the citrate salt form may cause dispensing delays at some pharmacies, so clinicians should use the full chemical name.

The FDA's current enforcement posture on compounded enclomiphene citrate is that it may be compounded by 503A pharmacies for individual patients when no FDA-approved commercially available drug is identical to the prescribed compound. [6] Since there is no commercially marketed enclomiphene citrate product in 2026, this condition is met, and 503A compounding remains permissible.

Understanding Enclomiphene Citrate vs. Clomiphene Citrate in Michigan

Some Michigan patients ask whether clomiphene citrate, a cheaper, FDA-approved generic available at most retail pharmacies, can substitute for enclomiphene. The short answer is that they are related but not identical. Clomiphene citrate is a 62:38 mixture of zuclomiphene (cis-isomer) and enclomiphene (trans-isomer). Zuclomiphene has a much longer half-life and estrogenic activity at some tissues. [7]

A phase 2 comparison trial showed that clomiphene-treated men had measurable zuclomiphene accumulation at 3 months, contributing to side effects including mood changes and reduced libido in a subset of patients, while enclomiphene-treated men showed no zuclomiphene accumulation. [4] That pharmacokinetic difference is the primary clinical rationale for preferring purified enclomiphene over generic clomiphene.

Clomiphene citrate 25 mg tablets are available at Michigan retail pharmacies for approximately $20 to $40 per month cash pay. If a Michigan Medicaid PA for enclomiphene is denied, some prescribers switch to off-label clomiphene citrate as a less expensive alternative while the appeal is processed. Patients should discuss this option explicitly with their provider rather than self-substituting.

The FDA approved clomiphene citrate (Clomid, Serophene) for female ovulatory dysfunction. [2] Its use in men is off-label, identical to enclomiphene in that respect, but the established generic supply chain makes prior authorization through Medicaid and commercial insurers somewhat easier to manage.

Lab Baselines Required Before Prescribing in Michigan

No Michigan or federal regulation mandates a specific lab panel before prescribing enclomiphene, but the standard of care, defined by the Endocrine Society guideline [3] and the AUA guideline [8], requires at minimum two morning total testosterone levels drawn on separate days, plus LH, FSH, and sex hormone-binding globulin (SHBG).

Additional labs recommended before initiating therapy:

• Complete blood count (CBC) to establish baseline hematocrit
• Comprehensive metabolic panel (CMP) for hepatic function baseline
• PSA for men over 40 (per AUA recommendation [8])
• Estradiol (E2) to assess baseline aromatase activity
• Prolactin to rule out hyperprolactinemia as a reversible cause of secondary hypogonadism

Labcorp and Quest Diagnostics both operate patient service centers across Michigan. LabCorp's self-pay testosterone panel (testosterone total, LH, FSH) runs approximately $60 to $90 cash pay without insurance. Some telehealth platforms, including HealthRX, provide requisition orders as part of the intake process so patients can draw labs locally before the video visit.

The Endocrine Society guideline explicitly states: "We suggest measuring morning total testosterone levels on at least two separate occasions before making a diagnosis of androgen deficiency." [3] Meeting that threshold before prescribing protects both the patient and the prescriber.